Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Treatments

Topic: Drug trials: efficacy and safety

Plain-language summary

RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions. We present the results of an analysis of observed data from a randomized, double-blind, placebo-controlled Phase 2b study. In this study, 684 subjects with mild to moderate Alzheimer's disease were randomized to receive 35 mg RVT-101, 15 mg RVT-101, or placebo as an adjunct to stable donepezil treatment. The study included a 24-week double-blind randomized phase and an optional, additional 24-week blinded extension. An analysis of covariance (ANCOVA) method was used to evaluate multiple endpoints on cognition and function based on observed data, including the ADAS-cog, CDR-SB, and ADCS-ADL at weeks 12, 24, 36, and 48. The proportion of subjects completing the study ranged from 86-89% from week 0 to week 24 and from 87-89% from week 24 to week 48. On ADAS-cog and ADCS-ADL respectively, subjects who received 35 mg RVT-101 achieved a 1.29 (p = 0.008) and 1.72 (p = 0.016) point benefit at week 12; a 1.63 (p = 0.007) and 2.11 (p = 0.016) point benefit at week 24; and a 1.82 (p = 0.018) and 2.34 (p = 0.048) point benefit at week 48, all compared to donepezil alone. Subjects who received 35 mg RVT-101 achieved a statistically significant benefit on CDR-SB compared to subjects who received donepezil alone only at 12 weeks after initiation of treatment. Mean ADAS-cog, ADCS-ADL and CDR-SB values for the 15-mg group were generally numerically superior to placebo but the differences were not statistically significant. In this analysis of subjects completing a Phase 2b study in subjects with mild-to-moderate Alzheimer's disease, the 35 mg dose of RVT-101 was shown to be effective in improving cognition and function as an adjunct to stable donepezil at multiple time points. Given the low drop-out rate, this analysis provides an accurate representation of the study. The 35 mg dose of RVT-101 will be advanced into a Phase 3 study in the second half of 2015.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. T. (2015). DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2015.08.154

Vancouver

Lombardo I, Ramaswamy G, Piscitelli SC, Friedhoff LT. DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study. Alzheimer s & Dementia. 2015. doi:10.1016/j.jalz.2015.08.154.

BibTeX

@article{lombardo2015-d54d3985,
  author  = {Lombardo, Ilise and Ramaswamy, Geetha and Piscitelli, Stephen C. and Friedhoff, Lawrence T.},
  title   = {{DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study}},
  journal = {Alzheimer s \& Dementia},
  year    = {2015},
  doi     = {10.1016/j.jalz.2015.08.154},
  url     = {https://doi.org/10.1016/j.jalz.2015.08.154}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 30 of the 58 points it could be judged on, which is 52 of 100. Total 52 of 100.30 of the 58 points we could judge = 52 of 100

Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 2 / 4 684 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 30 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100.
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “cholinesterase”

272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →